StockData
Kyverna Therapeutics, Inc. logo

Kyverna Therapeutics, Inc. (KYTX) stock

KYTXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 12, 2026Score 2/30
$4.70−0.06 (-1.26%)

Close on Nov 17, 2026Market cap $290.66MP/E –Yield –

Kyverna Therapeutics enterprise value

Enterprise value is market cap plus debt, minus cash: the value of the whole business to all its investors.

Kyverna Therapeutics's enterprise value was $140.72M on Nov 11, 2026, against $164.80M a year earlier. Over the last 3 years it ranged from -$202.60M to $347.29M, with a median of $3.58M.

Enterprise Value at the end of each year

PeriodPeriod endValueChange
2026Nov 11, 2026$140.72M-41.5%
2025Dec 31, 2025$240.56M–
2024Dec 31, 2024-$160.15M–

More Kyverna Therapeutics figures

See a number that looks wrong?